GLG News by General Cardiologists (US)

The field of anticoagulant compounds to be used in the prevention and  treatment of venous and arterial thrombosis is getting more crowded by the day. The new compounds are set to replace coumadin and heparin, to widely used medicines that have some serious disadvantages (heparin has also made...

Plasugrel is an attractive new medication for those patients undergoing cardiac catheterization with subsequent coronary intervention.  However, its niche will be with those patients at lower bleeding risk.  This is due to the fact that in the trial TRITON TIMI 38, prasugrel (which acts via...

Simcor does not remove the major complication that occurs with niacin which is flushing. I do not see this as a successful drug.

Patients with rare malignancies, especially those with already metastatic diseases, are being treated with novel oncologic agents.  However, as is being seen with many drugs, the hemodynamic consequences of these agents, in many cases a rise in blood pressure, may lead to cardiovascular consequences. ...

1:Most of our legislators are forcefully endorsing generic drug usage and importing cheaper drugs.2:As a physician specialist in Clinical Pharmacologist I am fully aware or the safety and efficacy pitfalls of poorly manufactured  drugs and have done clinical research documenting the risks of patients...

The oral anticoagulant market is huge and expanding. It is currently dominated by warfarin, which is widely prescribed, but which needs monthly blood draws to monitor the treatment intensity. The parenteral (non-oral) anticoagulant market is dominated by two players: [unfractioned] heparin (which is...

The long term efficacy of botulinum toxin Type A for the treatment of glabellar frown lines was recently discussed  in San Antonio, Texas at the 66th annual meeting of the American Association of Dermatology. Kawashima and other fellow Japanese investigators presented long-term (64 weeks)...

I anticipate vytorin and zetia sales will be down substantial when the IMS numbers come out tommorrow, but that this will be only the beginning of a negative trend for these scripts. I list below several reasons why.

One, twenty years ago I was the chairman of the government affairs committee of the American Society for Clinical Pharmacology and Therapeutics; under that role my committee was successful lobbying for approval new investigational drugs for possible treatment of AIDS. We were successful in getting the...

The announcement the new trial comparing Lipitor to Crestor  is interesting but not unexpected.  It is timed to end near the end of lipitor's patent. A win- which is likely- will certainly help AZN sell their drug against the much cheaper generic lipitor.